Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Sept 2009

Hughes Timothy, Saglio Giuseppe, Branford Susan, Soverini Simona, Kim Dong-Wook, Müller Martin C, Martinelli Giovanni, Cortes Jorge, Beppu Lan, Gottardi Enrico, Kim Dongho, Erben Philipp, Shou Yaping, Haque Ariful, Gallagher Neil, Radich Jerald, Hochhaus Andreas

Abstract excerpt

PURPOSE: Nilotinib is a second-generation tyrosine kinase inhibitor indicated for the treatment of patients with chronic myeloid leukemia (CML) in chronic phase (CP; CML-CP) and accelerated phase (AP; CML-AP) who are resistant to or intolerant of prior imatinib therapy. In this subanalysis of a phase II study of nilotinib in patients with imatinib-resistant or imatinib-intolerant CML-CP, the occurrence and impact...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Fusion Proteins, bcr-abl

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Expression Regulation, Leukemic

Share to Imatinib Mesylate

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Piperazines

Share to Pyrimidines

Source

Open in PubMed Open full text

Identifiers

PMID: 19652056
DOI: 10.1200/JCO.2009.21.8230
PMCID: PMC4979230

Genes

BCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.PMID 19652056Read ↗

Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase.Semantic proximity Read ↗

Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.Semantic proximity Read ↗

Impact of BCR-ABL mutations on patients with chronic myeloid leukemia.Semantic proximity Read ↗

BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase.Semantic proximity Read ↗

H396P mutation in chronic myeloid leukaemia patient on nilotinib - A case report.Semantic proximity Read ↗

Nilotinib: a second-generation tyrosine kinase inhibitor for chronic myeloid leukemia.Semantic proximity Read ↗

Improving frontline treatment for chronic myeloid leukemia: emerging evidence for use of nilotinib and dasatinib.Semantic proximity Read ↗

Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profile.Semantic proximity Read ↗

P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia.Semantic proximity Read ↗

Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL: a 36-month analysis of a phase I and II study.Semantic proximity Read ↗

Ultra-deep sequencing mutation analysis of the BCR/ABL1 kinase domain in newly diagnosed chronic myeloid leukemia patients.Semantic proximity Read ↗

The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.